[{"indications": "Indications\u00a0%s\n(From 8.2.3 Anti-lymphocyte monoclonal antibodies: British National Formulary)\nRituximab causes lysis of B lymphocytes. It is licensed for the treatment of chemotherapy-resistant or relapsed stage III\u2013IV follicular non-Hodgkin\u2019s lymphoma and, in combination with other chemotherapy, for previously untreated stage III\u2013IV follicular lymphoma, and for previously untreated or relapsed chronic lymphocytic leukaemia (see NICE guidance below). Rituximab is also licensed for maintenance therapy in patients with follicular non-Hodgkin\u2019s lymphoma that has responded to induction therapy (see NICE guidance below). It is also licensed for use in combination with other chemotherapy for the treatment of diffuse large B-cell non-Hodgkin\u2019s lymphoma (see NICE guidance below). Full resuscitation facilities should be at hand and as with other cytotoxics, treatment should be undertaken under the close supervision of a specialist. See section 10.1.3 for the role of rituximab in rheumatoid arthritis.Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion. Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.; severe active rheumatoid arthritis\r\n(%s\n(From RITUXIMAB: British National Formulary)\nRITUXIMAB)", "name": "RITUXIMAB", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.3 Anti-lymphocyte monoclonal antibodies"], "cautions": "Cautions\u00a0%s\n(From 8.2.3 Anti-lymphocyte monoclonal antibodies: British National Formulary)\nRituximab causes lysis of B lymphocytes. It is licensed for the treatment of chemotherapy-resistant or relapsed stage III\u2013IV follicular non-Hodgkin\u2019s lymphoma and, in combination with other chemotherapy, for previously untreated stage III\u2013IV follicular lymphoma, and for previously untreated or relapsed chronic lymphocytic leukaemia (see NICE guidance below). Rituximab is also licensed for maintenance therapy in patients with follicular non-Hodgkin\u2019s lymphoma that has responded to induction therapy (see NICE guidance below). It is also licensed for use in combination with other chemotherapy for the treatment of diffuse large B-cell non-Hodgkin\u2019s lymphoma (see NICE guidance below). Full resuscitation facilities should be at hand and as with other cytotoxics, treatment should be undertaken under the close supervision of a specialist. See section 10.1.3 for the role of rituximab in rheumatoid arthritis.Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion. Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.\u2014for full details consult product literature", "side-effects": "Side-effects\u00a0%s\n(From 8.2.3 Anti-lymphocyte monoclonal antibodies: British National Formulary)\nRituximab causes lysis of B lymphocytes. It is licensed for the treatment of chemotherapy-resistant or relapsed stage III\u2013IV follicular non-Hodgkin\u2019s lymphoma and, in combination with other chemotherapy, for previously untreated stage III\u2013IV follicular lymphoma, and for previously untreated or relapsed chronic lymphocytic leukaemia (see NICE guidance below). Rituximab is also licensed for maintenance therapy in patients with follicular non-Hodgkin\u2019s lymphoma that has responded to induction therapy (see NICE guidance below). It is also licensed for use in combination with other chemotherapy for the treatment of diffuse large B-cell non-Hodgkin\u2019s lymphoma (see NICE guidance below). Full resuscitation facilities should be at hand and as with other cytotoxics, treatment should be undertaken under the close supervision of a specialist. See section 10.1.3 for the role of rituximab in rheumatoid arthritis.Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion. Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.\u2014but for full details (including\r\nmonitoring and management of side-effects) consult product literature", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/70421.htm", "doses": ["See Doses"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit to mother outweighs\r\nrisk of B-lymphocyte depletion in fetus\u2014effective contraception required\r\nduring and for 12 months after treatment"}, {"indications": "Indications\u00a0see under Cytokine Modulators above; malignant disease\r\n(section 8.2.3)", "name": "RITUXIMAB - CYTOKINE MODULATORS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Cytokine modulators"], "cautions": "Cautions\u00a0section 8.2.3; predisposition\r\nto infection; hepatitis B virus\u2014monitor\r\nfor active infectionAlert card\u00a0Patients with rheumatoid\r\narthritis should be provided with the patient alert card before administration", "side-effects": "Side-effects\u00a0section 8.2.3 and under Cytokine Modulators; also dyspepsia; hypertension, hypotension; rhinitis,\r\nsore throat; asthenia, paraesthesia, migraine; arthralgia, muscle\r\nspasm; urticaria", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129937.htm", "doses": ["By intravenous infusion, adult, rheumatoid arthritis (in combination with\r\nmethotrexate), 1\u00a0g, repeated 2 weeks after initial infusion", "Patients should receive premedication\r\nbefore each infusion (consult product literature for details) and\r\nbe provided with a patient alert card"], "pregnancy": "Pregnancy\u00a0section 8.2.3"}, {"indications": "Indications\u00a0%s\n(From 8.2.3 Anti-lymphocyte monoclonal antibodies: British National Formulary)\nRituximab causes lysis of B lymphocytes. It is licensed for the treatment of chemotherapy-resistant or relapsed stage III\u2013IV follicular non-Hodgkin\u2019s lymphoma and, in combination with other chemotherapy, for previously untreated stage III\u2013IV follicular lymphoma, and for previously untreated or relapsed chronic lymphocytic leukaemia (see NICE guidance below). Rituximab is also licensed for maintenance therapy in patients with follicular non-Hodgkin\u2019s lymphoma that has responded to induction therapy (see NICE guidance below). It is also licensed for use in combination with other chemotherapy for the treatment of diffuse large B-cell non-Hodgkin\u2019s lymphoma (see NICE guidance below). Full resuscitation facilities should be at hand and as with other cytotoxics, treatment should be undertaken under the close supervision of a specialist. See section 10.1.3 for the role of rituximab in rheumatoid arthritis.Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion. Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.; severe active rheumatoid arthritis\r\n(%s\n(From RITUXIMAB: British National Formulary)\nRITUXIMAB)", "name": "RITUXIMAB - ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.3 Anti-lymphocyte monoclonal antibodies"], "cautions": "Cautions\u00a0%s\n(From 8.2.3 Anti-lymphocyte monoclonal antibodies: British National Formulary)\nRituximab causes lysis of B lymphocytes. It is licensed for the treatment of chemotherapy-resistant or relapsed stage III\u2013IV follicular non-Hodgkin\u2019s lymphoma and, in combination with other chemotherapy, for previously untreated stage III\u2013IV follicular lymphoma, and for previously untreated or relapsed chronic lymphocytic leukaemia (see NICE guidance below). Rituximab is also licensed for maintenance therapy in patients with follicular non-Hodgkin\u2019s lymphoma that has responded to induction therapy (see NICE guidance below). It is also licensed for use in combination with other chemotherapy for the treatment of diffuse large B-cell non-Hodgkin\u2019s lymphoma (see NICE guidance below). Full resuscitation facilities should be at hand and as with other cytotoxics, treatment should be undertaken under the close supervision of a specialist. See section 10.1.3 for the role of rituximab in rheumatoid arthritis.Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion. Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.\u2014for full details consult product literature", "side-effects": "Side-effects\u00a0%s\n(From 8.2.3 Anti-lymphocyte monoclonal antibodies: British National Formulary)\nRituximab causes lysis of B lymphocytes. It is licensed for the treatment of chemotherapy-resistant or relapsed stage III\u2013IV follicular non-Hodgkin\u2019s lymphoma and, in combination with other chemotherapy, for previously untreated stage III\u2013IV follicular lymphoma, and for previously untreated or relapsed chronic lymphocytic leukaemia (see NICE guidance below). Rituximab is also licensed for maintenance therapy in patients with follicular non-Hodgkin\u2019s lymphoma that has responded to induction therapy (see NICE guidance below). It is also licensed for use in combination with other chemotherapy for the treatment of diffuse large B-cell non-Hodgkin\u2019s lymphoma (see NICE guidance below). Full resuscitation facilities should be at hand and as with other cytotoxics, treatment should be undertaken under the close supervision of a specialist. See section 10.1.3 for the role of rituximab in rheumatoid arthritis.Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion. Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.\u2014but for full details (including\r\nmonitoring and management of side-effects) consult product literature", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/70421.htm", "doses": ["See Doses"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit to mother outweighs\r\nrisk of B-lymphocyte depletion in fetus\u2014effective contraception required\r\nduring and for 12 months after treatment"}]